ENGNW
enGene Holdings Inc. Warrants
NASDAQ · Healthcare · Biotechnology · CA
$0.21
−4.55%Year over year
Reported trailing growth
- Revenue
- -100.0%
- EBITDA
- -65.1%
- EBIT
- +22.0%
- EPS
- +20.0%
- Free cash flow
- -46.6%
- Operating cash flow
- -45.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +39.8%
- EPS
- +3.8%
Three-year CAGR
- Revenue
- —
- EBITDA
- —
- EBIT
- -97.7%
- Net income
- —
- EPS
- -56.8%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Apr 1, 2026